Espinel Eugenia, Agraz Irene, Ibernon Meritxell, Ramos Natalia, Fort Joan, Serón Daniel
Nephrology Department, Hospital Universitari Vall d'Hebron, Autonomous University of Barcelona, Passeig de la Vall d'Hebron 119-129, 08035 Barcelona, Spain.
J Clin Med. 2015 May 18;4(5):998-1009. doi: 10.3390/jcm4050998.
The majority of diabetic patients with renal involvement are not biopsied. Studies evaluating histological findings in renal biopsies performed in diabetic patients have shown that approximately one third of the cases will show pure diabetic nephropathy, one third a non-diabetic condition and another third will show diabetic nephropathy with a superimposed disease. Early diagnosis of treatable non-diabetic diseases in diabetic patients is important to ameliorate renal prognosis. The publication of the International Consensus Document for the classification of type 1 and type 2 diabetes has provided common criteria for the classification of diabetic nephropathy and its utility to stratify risk for renal failure has already been demonstrated in different retrospective studies. The availability of new drugs with the potential to modify the natural history of diabetic nephropathy has raised the question whether renal biopsies may allow a better design of clinical trials aimed to delay the progression of chronic kidney disease in diabetic patients.
大多数有肾脏受累的糖尿病患者未接受肾活检。评估糖尿病患者肾活检组织学结果的研究表明,约三分之一的病例将显示单纯糖尿病肾病,三分之一为非糖尿病性疾病,另外三分之一将显示糖尿病肾病合并其他疾病。早期诊断糖尿病患者可治疗的非糖尿病性疾病对于改善肾脏预后很重要。1型和2型糖尿病分类的国际共识文件的发布为糖尿病肾病的分类提供了通用标准,其在分层肾衰竭风险方面的效用已在不同的回顾性研究中得到证实。有潜力改变糖尿病肾病自然病程的新药的出现,引发了一个问题,即肾活检是否有助于更好地设计旨在延缓糖尿病患者慢性肾脏病进展的临床试验。